Spots Global Cancer Trial Database for peptide
Every month we try and update this database with for peptide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma | NCT01944709 | Melanoma | Dendritic cell ... | 18 Years - | Cantonal Hospital of St. Gallen | |
| Personalized Vaccine for Cancer Immunotherapy | NCT04879888 | Breast Cancer F... | Peptide pulsed ... | 18 Years - 65 Years | Universidad Nacional de Colombia | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | NCT02385669 | Melanoma | Ipilimumab 6MHP | 18 Years - | University of Virginia | |
| Safety Assessment of a Multipeptide-gene Vaccine in CML | NCT00455221 | Leukemia, Myelo... | Bcr-abl multipe... Cytokine gene a... | 18 Years - 65 Years | Tehran University of Medical Sciences | |
| A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma | NCT04072900 | Melanoma (Skin) | Peptide Anti-PD-1 rhGM-CSF Imiquimod 5% To... | 18 Years - 75 Years | Xiangya Hospital of Central South University | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | NCT00145158 | Malignant Melan... | 8 HLA-A2-restri... 8 HLA-A2-restri... | 18 Years - | Ludwig Institute for Cancer Research | |
| Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer | NCT00683358 | Pancreatic Canc... Pancreas Neopla... | VEGFR1-A24-1084... | 20 Years - 85 Years | Tokyo University | |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | Metastatic Mela... | NEO-PV-01 Nivolumab Adjuvant APX005M ipilimumab | 18 Years - | BioNTech SE | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer | NCT00683085 | Pancreatic Canc... Pancreas Neopla... | HLA-A*02:01-res... | 20 Years - 85 Years | Tokyo University | |
| Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors | NCT01711398 | All Solid Tumor... | Drug | 18 Years - | Elro Pharma | |
| Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | NCT00145145 | Malignant Melan... | MAGE-3.A1 pepti... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Phase I In-Vivo Peptide Applied in the Right Colon | NCT01722058 | Colon Lesions | Peptide applica... | 18 Years - | University of Michigan | |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | NCT03617328 | Melanoma | 6MHP Montanide ISA-5... polyICLC CDX-1127 | 18 Years - | University of Virginia | |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | NCT03380871 | Carcinoma, Non-... Lung Cancer Nonsquamous Non... | NEO-PV-01 Pembrolizumab Adjuvant Carboplatin Pemetrexed | 18 Years - | BioNTech SE | |
| Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | NCT00145158 | Malignant Melan... | 8 HLA-A2-restri... 8 HLA-A2-restri... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer | NCT00995358 | Esophageal Canc... | peptide | 20 Years - 80 Years | University of Yamanashi | |
| Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients | NCT06262139 | MRI Scan | MT218 injection | 18 Years - 90 Years | Molecular Theranostics LLC | |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer | NCT00995358 | Esophageal Canc... | peptide | 20 Years - 80 Years | University of Yamanashi | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma | NCT00938223 | Melanoma | 4-peptide and 1... | 18 Years - 85 Years | University of Virginia | |
| Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | NCT00090493 | Multiple Myelom... | MAGE-A3 MAGE-A3 AND NY-... | 18 Years - 70 Years | University of Arkansas | |
| A Phase I In-Vivo Peptide Applied in the Right Colon | NCT01722058 | Colon Lesions | Peptide applica... | 18 Years - | University of Michigan | |
| Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors | NCT01711398 | All Solid Tumor... | Drug | 18 Years - | Elro Pharma | |
| Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients | NCT06262139 | MRI Scan | MT218 injection | 18 Years - 90 Years | Molecular Theranostics LLC | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab | NCT02515227 | Melanoma | 6MHP Pembrolizumab | 18 Years - | University of Virginia | |
| PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer | NCT00669292 | Esophageal Canc... | URLC10-177, TTK... | 20 Years - 80 Years | Wakayama Medical University | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | NCT05025488 | Myelofibrosis Essential Throm... MPN | Peptide-based v... Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
